New drugs to fight drug-resistant tuberculosis
C25-modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis
This study is working on creating new versions of rifabutin, a medicine for tuberculosis, to help people with tough-to-treat drug-resistant strains of the disease, especially those who also have HIV, so they can have better treatment options.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project ID | NIH-11032609 on NIH RePORTER |
What this research studies
This research focuses on developing new analogs of rifabutin, a medication used to treat tuberculosis, to combat drug-resistant strains of the disease. The approach involves synthesizing modified versions of rifabutin that have shown increased potency against multidrug-resistant tuberculosis (MDR-TB) strains. By improving the effectiveness of these drugs, the research aims to provide better treatment options for patients who cannot be treated with standard therapies. The study will evaluate the pharmacokinetic properties of these new compounds to ensure they are safe and effective for use in patients, particularly those co-infected with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multidrug-resistant tuberculosis, especially those who are also living with HIV.
Not a fit: Patients with drug-sensitive tuberculosis or those who do not have tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from drug-resistant tuberculosis, potentially improving cure rates and reducing side effects.
How similar studies have performed: Other research has shown promise in developing new drug analogs for tuberculosis, indicating that this approach could be effective.
Where this research is happening
Hackensack, United States
- Hackensack University Medical Center — Hackensack, United States (Active)
Researchers
- Principal investigator: Ganapathy, Uday — Hackensack University Medical Center
- Study coordinator: Ganapathy, Uday
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.